4:48 PM ET
8-K
Investor Presentation
Camp4 Therapeutics Investor Presentation
CAMP4 Therapeutics held an Analyst Day meeting to present details on its planned Phase 1/2 ASCEND clinical trial of CMP-002 for SYNGAP1-related disorder. The company provided a comprehensive data presentation and updated its corporate pipeline overview, detailing the trial's design, inclusion criteria, and therapeutic dosing expectations.